Integrin β4 promotes DNA damage-related drug resistance in triple-negative breast cancer via TNFAIP2/IQGAP1/RAC1

Huan Fang; Wenlong Ren; Qiuxia Cui; Huichun Liang; Chuanyu Yang; Wenjing Liu; Xinye Wang; Xue Liu; Yujie Shi; Jing Feng; Ceshi Chen

doi:10.7554/eLife.88483

eLife (Oct 2023)

Integrin β4 promotes DNA damage-related drug resistance in triple-negative breast cancer via TNFAIP2/IQGAP1/RAC1

Huan Fang,
Wenlong Ren,
Qiuxia Cui,
Huichun Liang,
Chuanyu Yang,
Wenjing Liu,
Xinye Wang,
Xue Liu,
Yujie Shi,
Jing Feng,
Ceshi Chen

Affiliations

Huan Fang: Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, Yunnan, China; Kunming College of Life Sciences, University of Chinese Academy of Sciences, Kunming, Yunnan, China
Wenlong Ren: Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, Yunnan, China; School of Life Science, University of Science & Technology of China, Hefei, China
Qiuxia Cui: ORCiD; Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, Yunnan, China; Affiliated Hospital of Guangdong Medical University, Guangdong, China; Department of Breast Surgical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, China
Huichun Liang: Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, Yunnan, China
Chuanyu Yang: Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, Yunnan, China
Wenjing Liu: Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, Yunnan, China
Xinye Wang: Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, Yunnan, China
Xue Liu: Shanghai University of Medicine & Health Sciences Affiliated Sixth People’s Hospital South Campus, Shanghai, China
Yujie Shi: Department of Pathology, Henan Provincial People's Hospital, Zhengzhou University, Zhengzhou, China
Jing Feng: Shanghai University of Medicine & Health Sciences Affiliated Sixth People’s Hospital South Campus, Shanghai, China; The Second Affiliated Hospital of the Chinese University of Hong Kong (Shenzhen), Shenzhen, China; School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangdong Province, Guangzhou, China
Ceshi Chen: ORCiD; Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, Yunnan, China; Academy of Biomedical Engineering, Kunming Medical University, Kunming, China; The Third Affiliated Hospital, Kunming Medical University, Kunming, China

DOI: https://doi.org/10.7554/eLife.88483
Journal volume & issue: Vol. 12

Abstract

Read online

Anti-tumor drug resistance is a challenge for human triple-negative breast cancer (TNBC) treatment. Our previous work demonstrated that TNFAIP2 activates RAC1 to promote TNBC cell proliferation and migration. However, the mechanism by which TNFAIP2 activates RAC1 is unknown. In this study, we found that TNFAIP2 interacts with IQGAP1 and Integrin β4. Integrin β4 activates RAC1 through TNFAIP2 and IQGAP1 and confers DNA damage-related drug resistance in TNBC. These results indicate that the Integrin β4/TNFAIP2/IQGAP1/RAC1 axis provides potential therapeutic targets to overcome DNA damage-related drug resistance in TNBC.

Published in eLife

ISSN: 2050-084X (Online)
Publisher: eLife Sciences Publications Ltd
Country of publisher: United Kingdom
LCC subjects: Medicine; Science: Biology (General)
Website: https://elifesciences.org

About the journal

Abstract

Keywords